Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2010-04-29
2011-10-25
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S468000, C424S464000, C424S474000, C424S472000
Reexamination Certificate
active
08043630
ABSTRACT:
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
REFERENCES:
patent: 4088798 (1978-05-01), Michaelis
patent: 4309406 (1982-01-01), Guley et al.
patent: 4629620 (1986-12-01), Lindahl et al.
patent: 4756911 (1988-07-01), Drost et al.
patent: 4789549 (1988-12-01), Khan
patent: 4816264 (1989-03-01), Philips et al.
patent: 4891223 (1990-01-01), Ambegaonkar
patent: 4892742 (1990-01-01), Shah
patent: 5151273 (1992-09-01), Korsalko-Wabnegg et al.
patent: 5190760 (1993-03-01), Baker
patent: 5391378 (1995-02-01), Sanderson
patent: 5458887 (1995-10-01), Chen et al.
patent: 5458888 (1995-10-01), Chen
patent: 5464633 (1995-11-01), Conte et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5549913 (1996-08-01), Colombo et al.
patent: 5654005 (1997-08-01), Chen et al.
patent: 5736159 (1998-04-01), Chen et al.
patent: 5783212 (1998-07-01), Fassihi et al.
patent: 5827538 (1998-10-01), Cussler et al.
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5861173 (1999-01-01), Nishioka et al.
patent: 5876752 (1999-03-01), Herbig et al.
patent: 5891474 (1999-04-01), Busetti et al.
patent: 5916595 (1999-06-01), Chen et al.
patent: 5955106 (1999-09-01), Moeckel et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6099859 (2000-08-01), Cheng et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6149940 (2000-11-01), Maggi et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6372255 (2002-04-01), Saslawski et al.
patent: 6475521 (2002-11-01), Timmins et al.
patent: 2003/0091630 (2003-05-01), Louie-Helm et al.
patent: 2220038 (1999-07-01), None
patent: 4432757 (1996-03-01), None
patent: 0526862 (1993-02-01), None
patent: 1330829 (1973-09-01), None
patent: 1428426 (1976-03-01), None
patent: WO 98/08515 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 99/47128 (1999-09-01), None
Baichwal and Neville, “Drug Delivery Partnership: Culturing innovation and enhancing medications using oral drug delivery,” Drug Delivery Teohnol., vol. 2, No. 3, pp. 65-68 (2002).
Ghanem, et al., “The effect of a second laminated gelatin film on the release rate of sulfadiazine from gelatin-gel matrix”, Pharmazie, vol. 34, No, 7. pp. 415-417 (1979).
Kallstrand and Ekman, “Membrane-coated tablets: a system for the controlled release of drugs,” Journal of Pharmaceutical Sciences, vol. 72, No. 7, pp. 772-775 (1983).
Lee, “Controlled release of dual drug-loaded hydroxypropyl methylcellulose matrix tablet using drug-containing polymeric coatings”, International Journal of Pharmaceutics, vol. 188, pp. 71-80, (1999).
Maggi, et al., “Highly swellable, multi-layer tablets to prolong the residence time of the delivery device in the stomach,” J. Controlled Release, vol. 64, pp. 332-334 (2000).
Conte, et al., “Modulation of the dissolution profiles from Geomatrix® multi-layer matrix tablets containing drugs of different solubility”, Biomaterials, vol. 17, No. 9, pp. 889-896 (1996).
Deshpande, et al., “Development of a novel controlled-release system for gastric retention”, Pharmaceutical Research, vol. 14, No. 6, pp. 815-819 (1997).
Fukui, et al,, “Studies on applicability of press-coated tablets using hydroxypropylcellulose (HPC) in the outer shell for timed-release preparations”, Journal of Controlled Release, vol. 68, pp. 215-223 (2000).
Halsas, et al., “Biopharmaceutical evaluation of time-controlled press-coated tablets containing polymers to adjust drug release”, Eur. J. Drug Metab Pharmacokinet., vol. 23, No. 2, pp. 190-196 (1998).
Halsas, et al., “Effect of different combinations of hydroxypropylmethyl cellulose on bioavailability of ibuprofen from press-coated time-controlled tablets”, S.T.P. Pharma Sciences, vol. 8, No. 3, pp. 155-162 (1998).
Ito, et al., “Investigation of Compressed Coating Tablet Swelling with Water as New Dosage Form for Elderly Patients”, Jpn. J. Hosp. Pharm., vol. 20, No. 1, pp. 41-48 (1994).
Maggie, et al., “Highly swellable, multi-layer tablets to prolong the residence time of the delivery device in the stomach,” J. Controlled Release, vol. 64, pp. 332-334 (2000).
Pillay, et al., “In situ electrolyte interactions in a disk-compressed configuration system for up-curving and constant drug delivery”, Journal of Controlled Release, vol. 67, No. 1, pp. 55-65 (2000).
Sirkia, et al., “Use of hydrophyllic polymers to control drug release from press-coated oxybutynin hydrochloric tablets”, S.T.P. Pharma Sciences, vol. 3, No. 6, pp. 453-458 (1993).
Sirkia, et al., “Biopharmaceutical evaluation of new prolonged-release press-coated ibuprofen tablets containing sodium alginate to adjust drug release”, International Journal of Pharmaceutics, vol. 107, No. 3, pp. 179-187 (1994).
Sirkia, et al., “Development and biopharmaceutical evaluations of a new press-coated prolonged-release salbutamol sulphate tablet in man”, European Journal of Pharmaceutical Sciences, vol. 1, No. 4, pp. 195-201 (1994).
Berner Bret
Gusler Gloria
Louie-Helm Jenny
Shell John N.
Depomed Inc.
Harlocker Susan L.
King & Spalding LLP
Mohr Judy M.
Padmanabhan Sreeni
LandOfFree
Shell-and-core dosage form approaching zero-order drug release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Shell-and-core dosage form approaching zero-order drug release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Shell-and-core dosage form approaching zero-order drug release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4283188